Hereditary Thrombophilia in the Era of COVID-19
Oana Viola Bădulescu, Paul Dan Sîrbu, Nina Filip, Gabriela Bordeianu, Elena Cojocaru, Cristian Constantin Budacu, Minerva Codruța Bădescu, Iris Bararu‐Bojan, Bogdan Veliceasa, Manuela Ciocoiu
Abstract
Thrombophilia, also called hypercoagulability or prothrombotic condition, usually reflects a certain imbalance that occurs either in the coagulation cascade or in the anticoagulation/fibrinolytic system. A similar imbalance may be induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Thrombotic complications are associated with multiorgan failure and increased mortality. In this context, activation of coagulation and thrombocytopenia appeared as prognostic markers in COVID-19. Our work provides a structured and updated analysis of inherited thrombophilia and its involvement in COVID-19, emphasizing the importance of diagnosing and initiating thromboprophylaxis. Since the state of hypercoagulation is directly correlated with COVID-19, we consider that studies on the genetic profiles of proteins involved in thrombophilia in patients who have had COVID-19 and thrombotic events are of great importance, both in treating and in preventing deaths due to COVID-19.